Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ze-Rui Wu"'
Autor:
Hang Zhou, Ze-Rui Wu, Xiang-Yang Chen, Le-Shu Zhang, Jin-Cheng Zhang, Sakarie Mustafe Hidig, Shuo Feng, Zhi Yang
Publikováno v:
BMC Musculoskeletal Disorders, Vol 24, Iss 1, Pp 1-14 (2023)
Abstract Background The purpose of this study was to measure the femoral prosthesis flexion angle (FPFA) in total knee arthroplasty (TKA) using three-dimensional reconstruction, and to assess the differences in early clinical efficacy between patient
Externí odkaz:
https://doaj.org/article/ef2abcbc2fae453387b27176857190d5
Autor:
Ze Rui Wu, Lichong Yan, Yan Ting Liu, Lei Cao, Yu Hang Guo, Yong Zhang, Hong Yao, Lin Cai, Han Bing Shang, Wei Wei Rui, Gang Yang, Xiao Biao Zhang, Hao Tang, Yu Wang, Jin Yan Huang, Yong Xu Wei, Wei Guo Zhao, Bing Su, Zhe Bao Wu
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
LncRNA H19 has been shown to be aberrantly expressed in different cancers. Here, the authors show that H19 lncRNA is downregulated in pituitary adenomas and H19 is able to impede pituitary tumorigenesis via disruption of 4E-BPB1 and Raptor interactio
Externí odkaz:
https://doaj.org/article/06d60b35e5174563a00cf014ab758ffe
Autor:
Lin, Cai, Ze-Rui, Wu, Lei, Cao, Jia-Dong, Xu, Jiang-Long, Lu, Cheng-de, Wang, Jing-Hao, Jin, Zhe-Bao, Wu, Zhi-Peng, Su
Publikováno v:
Acta Pharmacologica Sinica. 43:2386-2396
ACT001, derived from traditional herbal medicine, is a novel compound with effective anticancer activity in clinical trials. However, little is known regarding its role in pituitary adenomas. Here, we demonstrated that ACT001 suppressed cell prolifer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbdc5c6e11bcbb4febcb57b38e4ab542
https://doi.org/10.1038/s41401-021-00856-5
https://doi.org/10.1038/s41401-021-00856-5
Autor:
Ze Rui Wu, Yong Zhang, Lin Cai, Shao Jian Lin, Zhi Peng Su, Yong Xu Wei, Han Bing Shang, Wen Lei Yang, Wei Guo Zhao, Zhe Bao Wu
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteri
Externí odkaz:
https://doaj.org/article/58d4856b04d74c5ebc9c9dc59aeb05bc
Publikováno v:
Applied Thermal Engineering. 219:119492
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75f1d9ca2ce9d2d978f6121d7f3f6712
https://doi.org/10.1016/j.applthermaleng.2022.119492
https://doi.org/10.1016/j.applthermaleng.2022.119492
Autor:
Jinyan Huang, Yu Wang, Lin Cai, Wei Wei Rui, Gang Yang, Zhe Bao Wu, Yu Hang Guo, Xiao Biao Zhang, Hao Tang, Wei Guo Zhao, Hong Yao, Lichong Yan, Han Bing Shang, Yong Zhang, Ze Rui Wu, Lei Cao, Yong Xu Wei, Yan Ting Liu, Bing Su
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-14 (2018)
Nature Communications
Nature Communications
Aberrant expression of long noncoding RNA H19 has been associated with tumour progression, but the underlying molecular tumourigenesis mechanisms remain largely unknown. Here, we report that H19 expression is frequently downregulated in human primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1316fa39ffc7026daf2a50c76a4a51a
http://link.springer.com/article/10.1038/s41467-018-06853-3
http://link.springer.com/article/10.1038/s41467-018-06853-3
Autor:
Yu Hang Guo, Zhi Gen Leng, Lin Cai, Ze Rui Wu, Zhe Bao Wu, Li Fei Wei, Shao Jian Lin, Jiang Long Lu, Zhi Peng Su, Kunlin Jin, Qi Chuan Zhuge
Publikováno v:
Endocrine. 52:641-651
Dopamine agonists (DAs) are the first-line treatment of prolactinomas. They function through the dopamine 2 receptor (D2R) in the tumor cells. Endocan, also called endothelial cell-specific molecule-1 (ESM1), has been described as a marker of neoangi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcb2683f4c1a1f11590ebb65a84f1f29
https://doi.org/10.1007/s12020-015-0824-2
https://doi.org/10.1007/s12020-015-0824-2
Autor:
Xun Zhang, Han Bing Shang, Ya Jun Xue, Hao Tang, Lin Cai, Weidong Le, Zhe Bao Wu, Yu Hang Guo, Wei Guo Zhao, Shao Jian Lin, Mei Qing Lou, Ze Rui Wu, Wenxiu Zhao, Zhi Gen Leng
Dopamine agonists such as bromocriptine and cabergoline have been successfully used in the treatment of pituitary prolactinomas and other neuroendocrine tumors. However, their therapeutic mechanisms are not fully understood. In this study we demonstr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9dc7717c2389f089e22d321b0d8e733
https://europepmc.org/articles/PMC5584849/
https://europepmc.org/articles/PMC5584849/
Autor:
Wei Guo Zhao, Han Bing Shang, Yong Xu Wei, Zhi Peng Su, Shao Jian Lin, Ze Rui Wu, Lin Cai, Zhe Bao Wu, Yong Zhang, Wen Lei Yang
Publikováno v:
International Journal of Endocrinology, Vol 2016 (2016)
International Journal of Endocrinology
International Journal of Endocrinology
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs).Methods. Twenty-five patients met the criteria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58b9f3dda8b63277d67464e00aa9083b
https://doaj.org/article/58d4856b04d74c5ebc9c9dc59aeb05bc
https://doaj.org/article/58d4856b04d74c5ebc9c9dc59aeb05bc